Legend Biotech (LEGN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to standard treatments, according to recent phase 3 trial results. The study highlights CARVYKTI®’s potential as a transformative cell therapy, achieving an 89% MRD-negative rate in treated patients, which could enhance progression-free and overall survival outcomes. This promising data may bolster investor confidence in Legend Biotech’s innovative approach to cancer treatment.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
